Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma
Purpose To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma. Design Retrospective chart review. Methods Review of 75 eyes treated with intravitreal inject...
Gespeichert in:
| Veröffentlicht in: | American journal of ophthalmology 2007-06, Vol.143 (6), p.1034-1035 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1035 |
|---|---|
| container_issue | 6 |
| container_start_page | 1034 |
| container_title | American journal of ophthalmology |
| container_volume | 143 |
| creator | Frenkel, Ronald E.P Mani, Lakshmi Toler, Allison R Frenkel, Max P.C |
| description | Purpose To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma. Design Retrospective chart review. Methods Review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml). The effect of these injections on IOP was analyzed. Most patients received prophylactic IOP-lowering medications. Results The mean preinjection IOP based on the first injection of each patient was 14 ± 3 mm Hg; at one minute postinjection, 38 ± 14 mm Hg, at three to 10 minutes was 34 ± 9 mm Hg, and at 11 to 20 minutes was 26 ±10 mm Hg, respectively. Most patients’ IOPs had significantly diminished by 30 minutes postinjection. Conclusion Pegaptanib injections result in a significant transient rise in IOP that considerably diminishes by 30 minutes postinjection but can take up to one hour. This may be damaging to the optic nerve, particularly in patients with advanced glaucoma. |
| doi_str_mv | 10.1016/j.ajo.2007.01.052 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70546315</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939407001225</els_id><sourcerecordid>70546315</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-d704d184e46f65cc0b9188a6a8f31ae07f6373dcd3f9424b4aa6df4b18d452113</originalsourceid><addsrcrecordid>eNp9klGL1DAUhYMo7rj6A3yRgij60JrbpkmDIMiyrgMrDqj4GG7TZE3tJLNJK-y_N-MMDOyDT0nId25uzrmEPAdaAQX-bqxwDFVNqagoVLStH5AVdEKW0El4SFaU0rqUjWRn5ElKYz5ywcRjcgairZkQsCJm7eeIQS8TxmITTUpLNMWltUbPqQi22Jgb3M3oXV-8-YJ6uTH-bbH2Y753wafC-WKDszM-4z_d_KtAP_zbhGUuriZcdNjiU_LI4pTMs-N6Tn58uvx-8bm8_nq1vvh4XWrG2VwOgrIBOmYYt7zVmvYSug45drYBNFRY3ohm0ENjJatZzxD5YFkP3cDaGqA5J68PdXcx3C4mzWrrkjbThN6EJSlBW8YbaDP48h44hiX63JsCzpjkHWt5puBA6RhSisaqXXRbjHcKqNonoEaVE1D7BBQFlRPImhfHyku_NcNJcbQ8A6-OACaNk43otUsnTsqmk7LL3PsDZ7Jhf5yJKulsszaDi9l8NQT33zY-3FPryXmXH_xt7kw6_ValWlH1bT8q-0mhglKo67b5C-Q8t1U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1644968456</pqid></control><display><type>article</type><title>Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Frenkel, Ronald E.P ; Mani, Lakshmi ; Toler, Allison R ; Frenkel, Max P.C</creator><creatorcontrib>Frenkel, Ronald E.P ; Mani, Lakshmi ; Toler, Allison R ; Frenkel, Max P.C</creatorcontrib><description>Purpose To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma. Design Retrospective chart review. Methods Review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml). The effect of these injections on IOP was analyzed. Most patients received prophylactic IOP-lowering medications. Results The mean preinjection IOP based on the first injection of each patient was 14 ± 3 mm Hg; at one minute postinjection, 38 ± 14 mm Hg, at three to 10 minutes was 34 ± 9 mm Hg, and at 11 to 20 minutes was 26 ±10 mm Hg, respectively. Most patients’ IOPs had significantly diminished by 30 minutes postinjection. Conclusion Pegaptanib injections result in a significant transient rise in IOP that considerably diminishes by 30 minutes postinjection but can take up to one hour. This may be damaging to the optic nerve, particularly in patients with advanced glaucoma.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2007.01.052</identifier><identifier>PMID: 17524771</identifier><identifier>CODEN: AJOPAA</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Antihypertensive Agents - therapeutic use ; Aptamers, Nucleotide - adverse effects ; Aptamers, Nucleotide - therapeutic use ; Biological and medical sciences ; Chronic Disease ; Glaucoma ; Glaucoma and intraocular pressure ; Glaucoma, Open-Angle - complications ; Glaucoma, Open-Angle - drug therapy ; Humans ; Injections ; Intraocular Pressure - drug effects ; Macular degeneration ; Macular Degeneration - complications ; Macular Degeneration - drug therapy ; Medical sciences ; Miscellaneous ; Ophthalmology ; Retrospective Studies ; Time Factors ; Tonometry, Ocular ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vitreous Body</subject><ispartof>American journal of ophthalmology, 2007-06, Vol.143 (6), p.1034-1035</ispartof><rights>Elsevier Inc.</rights><rights>2007 Elsevier Inc.</rights><rights>2008 INIST-CNRS</rights><rights>Copyright Elsevier Limited Jun 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-d704d184e46f65cc0b9188a6a8f31ae07f6373dcd3f9424b4aa6df4b18d452113</citedby><cites>FETCH-LOGICAL-c464t-d704d184e46f65cc0b9188a6a8f31ae07f6373dcd3f9424b4aa6df4b18d452113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajo.2007.01.052$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19938998$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17524771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frenkel, Ronald E.P</creatorcontrib><creatorcontrib>Mani, Lakshmi</creatorcontrib><creatorcontrib>Toler, Allison R</creatorcontrib><creatorcontrib>Frenkel, Max P.C</creatorcontrib><title>Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Purpose To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma. Design Retrospective chart review. Methods Review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml). The effect of these injections on IOP was analyzed. Most patients received prophylactic IOP-lowering medications. Results The mean preinjection IOP based on the first injection of each patient was 14 ± 3 mm Hg; at one minute postinjection, 38 ± 14 mm Hg, at three to 10 minutes was 34 ± 9 mm Hg, and at 11 to 20 minutes was 26 ±10 mm Hg, respectively. Most patients’ IOPs had significantly diminished by 30 minutes postinjection. Conclusion Pegaptanib injections result in a significant transient rise in IOP that considerably diminishes by 30 minutes postinjection but can take up to one hour. This may be damaging to the optic nerve, particularly in patients with advanced glaucoma.</description><subject>Aged</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Aptamers, Nucleotide - adverse effects</subject><subject>Aptamers, Nucleotide - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Chronic Disease</subject><subject>Glaucoma</subject><subject>Glaucoma and intraocular pressure</subject><subject>Glaucoma, Open-Angle - complications</subject><subject>Glaucoma, Open-Angle - drug therapy</subject><subject>Humans</subject><subject>Injections</subject><subject>Intraocular Pressure - drug effects</subject><subject>Macular degeneration</subject><subject>Macular Degeneration - complications</subject><subject>Macular Degeneration - drug therapy</subject><subject>Medical sciences</subject><subject>Miscellaneous</subject><subject>Ophthalmology</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><subject>Tonometry, Ocular</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vitreous Body</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9klGL1DAUhYMo7rj6A3yRgij60JrbpkmDIMiyrgMrDqj4GG7TZE3tJLNJK-y_N-MMDOyDT0nId25uzrmEPAdaAQX-bqxwDFVNqagoVLStH5AVdEKW0El4SFaU0rqUjWRn5ElKYz5ywcRjcgairZkQsCJm7eeIQS8TxmITTUpLNMWltUbPqQi22Jgb3M3oXV-8-YJ6uTH-bbH2Y753wafC-WKDszM-4z_d_KtAP_zbhGUuriZcdNjiU_LI4pTMs-N6Tn58uvx-8bm8_nq1vvh4XWrG2VwOgrIBOmYYt7zVmvYSug45drYBNFRY3ohm0ENjJatZzxD5YFkP3cDaGqA5J68PdXcx3C4mzWrrkjbThN6EJSlBW8YbaDP48h44hiX63JsCzpjkHWt5puBA6RhSisaqXXRbjHcKqNonoEaVE1D7BBQFlRPImhfHyku_NcNJcbQ8A6-OACaNk43otUsnTsqmk7LL3PsDZ7Jhf5yJKulsszaDi9l8NQT33zY-3FPryXmXH_xt7kw6_ValWlH1bT8q-0mhglKo67b5C-Q8t1U</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Frenkel, Ronald E.P</creator><creator>Mani, Lakshmi</creator><creator>Toler, Allison R</creator><creator>Frenkel, Max P.C</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma</title><author>Frenkel, Ronald E.P ; Mani, Lakshmi ; Toler, Allison R ; Frenkel, Max P.C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-d704d184e46f65cc0b9188a6a8f31ae07f6373dcd3f9424b4aa6df4b18d452113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Aptamers, Nucleotide - adverse effects</topic><topic>Aptamers, Nucleotide - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Chronic Disease</topic><topic>Glaucoma</topic><topic>Glaucoma and intraocular pressure</topic><topic>Glaucoma, Open-Angle - complications</topic><topic>Glaucoma, Open-Angle - drug therapy</topic><topic>Humans</topic><topic>Injections</topic><topic>Intraocular Pressure - drug effects</topic><topic>Macular degeneration</topic><topic>Macular Degeneration - complications</topic><topic>Macular Degeneration - drug therapy</topic><topic>Medical sciences</topic><topic>Miscellaneous</topic><topic>Ophthalmology</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><topic>Tonometry, Ocular</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vitreous Body</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frenkel, Ronald E.P</creatorcontrib><creatorcontrib>Mani, Lakshmi</creatorcontrib><creatorcontrib>Toler, Allison R</creatorcontrib><creatorcontrib>Frenkel, Max P.C</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frenkel, Ronald E.P</au><au>Mani, Lakshmi</au><au>Toler, Allison R</au><au>Frenkel, Max P.C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>143</volume><issue>6</issue><spage>1034</spage><epage>1035</epage><pages>1034-1035</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><coden>AJOPAA</coden><abstract>Purpose To determine if pegaptanib (Macugen) [Eyetech Pharmaceuticals; Pfizer Inc, New York, New York, USA] injections cause adverse intraocular pressure (IOP) effects in patients with and without glaucoma. Design Retrospective chart review. Methods Review of 75 eyes treated with intravitreal injections of pegaptanib (0.09 ml). The effect of these injections on IOP was analyzed. Most patients received prophylactic IOP-lowering medications. Results The mean preinjection IOP based on the first injection of each patient was 14 ± 3 mm Hg; at one minute postinjection, 38 ± 14 mm Hg, at three to 10 minutes was 34 ± 9 mm Hg, and at 11 to 20 minutes was 26 ±10 mm Hg, respectively. Most patients’ IOPs had significantly diminished by 30 minutes postinjection. Conclusion Pegaptanib injections result in a significant transient rise in IOP that considerably diminishes by 30 minutes postinjection but can take up to one hour. This may be damaging to the optic nerve, particularly in patients with advanced glaucoma.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>17524771</pmid><doi>10.1016/j.ajo.2007.01.052</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9394 |
| ispartof | American journal of ophthalmology, 2007-06, Vol.143 (6), p.1034-1035 |
| issn | 0002-9394 1879-1891 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70546315 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Aged Antihypertensive Agents - therapeutic use Aptamers, Nucleotide - adverse effects Aptamers, Nucleotide - therapeutic use Biological and medical sciences Chronic Disease Glaucoma Glaucoma and intraocular pressure Glaucoma, Open-Angle - complications Glaucoma, Open-Angle - drug therapy Humans Injections Intraocular Pressure - drug effects Macular degeneration Macular Degeneration - complications Macular Degeneration - drug therapy Medical sciences Miscellaneous Ophthalmology Retrospective Studies Time Factors Tonometry, Ocular Vascular Endothelial Growth Factor A - antagonists & inhibitors Vitreous Body |
| title | Intraocular Pressure Effects of Pegaptanib (Macugen) Injections in Patients With and Without Glaucoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T18%3A01%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Intraocular%20Pressure%20Effects%20of%20Pegaptanib%20(Macugen)%20Injections%20in%20Patients%20With%20and%20Without%20Glaucoma&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Frenkel,%20Ronald%20E.P&rft.date=2007-06-01&rft.volume=143&rft.issue=6&rft.spage=1034&rft.epage=1035&rft.pages=1034-1035&rft.issn=0002-9394&rft.eissn=1879-1891&rft.coden=AJOPAA&rft_id=info:doi/10.1016/j.ajo.2007.01.052&rft_dat=%3Cproquest_cross%3E70546315%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1644968456&rft_id=info:pmid/17524771&rft_els_id=S0002939407001225&rfr_iscdi=true |